Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072104 | 0.94 | FFAR4 (0.33) | IDO1FFAR4 | |
| SCHEMBL6072284 | 0.94 | IDO1 (0.33) | IDO1FFAR4SSTR5KDM4EALDH1A1 | |
| SCHEMBL6071815 | 0.90 | SMN1; SMN2 (0.34) | IDO1SSTR5ALDH1A1MAPT | |
| SCHEMBL6072322 | 0.90 | PDE10A (0.32) | IDO1FFAR4 | |
| SCHEMBL6072191 | 0.90 | ACLY (0.38) | IDO1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6072196 | 0.89 | HSD17B10 (0.36) | IDO1KDM4EALDH1A1ACLYPTPN1 | |
| SCHEMBL6072777 | 0.89 | AKR1C3 (0.35) | IDO1SSTR5KDM4EALDH1A1LMNA | |
| SCHEMBL6072844 | 0.88 | ACLY (0.41) | IDO1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6072447 | 0.88 | IDO1 (0.33) | IDO1 | |
| SCHEMBL6072164 | 0.88 | ACLY (0.38) | FFAR4SSTR5KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | IDO1 1813/4885FFAR4 272/4885SSTR5 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.